AnaptysBio Inc
$ 56.07
3.37%
12 Jun - close price
- Market Cap 1,631,688,000 USD
- Current Price $ 56.07
- High / Low $ 56.25 / 54.30
- Stock P/E N/A
- Book Value 0.44
- EPS -1.02
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE -1.14 %
- 52 Week High 72.36
- 52 Week Low 11.40
About
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Analyst Target Price
$87.09
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-03 | 2025-11-04 | 2025-08-07 | 2025-05-05 | 2025-02-27 | 2024-11-04 | 2024-08-05 | 2024-05-09 | 2024-03-12 | 2023-11-02 | 2023-08-06 |
| Reported EPS | -1.8432 | 1.58 | 0.52 | -1.34 | -1.28 | -0.72 | -1.14 | -1.71 | -1.64 | -1.59 | -1.41 | -1.5 |
| Estimated EPS | -1.07 | 0.93 | -1.25 | -1.58 | -1.46 | -1.7049 | -1.61 | -0.93 | -1.6 | -1.6 | -1.89 | -1.74 |
| Surprise | -0.7732 | 0.65 | 1.77 | 0.24 | 0.18 | 0.9849 | 0.47 | -0.78 | -0.04 | 0.01 | 0.48 | 0.24 |
| Surprise Percentage | -72.2617% | 69.8925% | 141.6% | 15.1899% | 12.3288% | 57.7688% | 29.1925% | -83.871% | -2.5% | 0.625% | 25.3968% | 13.7931% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.25 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANAB
2026-06-12 19:39:16
An affiliate of ANAPTYSBIO, INC (ANAB) has filed a Form 144, indicating proposed sales of common stock by Dennis Mulroy. The filing details multiple dispositions planned between May 15, 2026, and June 12, 2026, including specific trade dates, share counts, and gross proceeds. This is a routine notice for proposed sales and does not confirm that the sales have already occurred.
2026-06-12 11:39:16
HC Wainwright has issued its Q2 2026 earnings forecast for AnaptysBio (NASDAQ:ANAB), projecting a loss of $0.84 per share and reiterating a "Buy" rating with a $95 price target. Other analysts generally maintain a "Moderate Buy" consensus for the stock, with an average price target of $81.82, despite some recent downgrades to "Hold." AnaptysBio shares were up 4.1% and recently traded at $54.24, following a wider-than-expected quarterly loss but revenue beat.
2026-06-11 21:10:22
A Form 144 filing indicates that Morgan Stanley Smith Barney LLC intends to sell 35,000 shares of AnaptysBio, Inc. (ANAB) common stock on June 11, 2026, through a stock option exercise, valued at $1,848,750. The filing also details multiple past open-market dispositions by Dennis Mulroy between May 15, 2026, and June 10, 2026, involving sales ranging from 10,000 to over 22,987 shares with disclosed gross proceeds. The proposed sale and previous transactions are part of regulatory disclosures affecting transparency in the stock market.
2026-06-10 20:40:07
ANAPTYSBIO, INC (ANAB) affiliate Dennis Mulroy filed a Form 144, disclosing a 20,000-share stock option exercise on June 10, 2026, and multiple sales of common stock between May 15 and June 9, 2026. The filing details the number of shares sold and the gross proceeds for each transaction. This Form 144 indicates proposed and completed dispositions by an affiliate.
2026-06-10 12:40:07
HC Wainwright & Co. has initiated coverage of AnaptysBio (ANAB) with a Buy rating and a price target of $95.00, citing the company's clinical trials and product development. GuruFocus also indicates ANAB is undervalued by 18.8% with a GF Value™ of $63.59, despite a moderate GF Score™ of 63/100 and recent insider selling activity. Investors are advised to research thoroughly due to mixed signals regarding profitability and insider confidence.
2026-06-10 11:40:07
H.C. Wainwright has initiated coverage on AnaptysBio Inc. (NASDAQ:ANAB) with a buy rating and a price target of $95.00, following the spinoff of First Tracks Bio. The firm highlights AnaptysBio's focus on royalty-bearing assets, aggressive stock buybacks, and a projected turn to profitability in fiscal 2026. The stock's impressive 223% return over the past year is also noted.
